1
|
Romero A, Ashcraft L, Chandra A, DiMassa V, Cremin P, Collibee SE, Chuang C, Hartman J, Hwee DT, St Jean D, Malinowski J, DeBenedetto M, Moebius D, Payette J, Vargas R, Yeoman J, Motani A, Reagan J, Malik FI, Morgan BP. Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility. J Med Chem 2024. [PMID: 38729623 DOI: 10.1021/acs.jmedchem.3c02413] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/12/2024]
Abstract
Cardiac myosin activation has been shown to be a viable approach for the treatment of heart failure with reduced ejection fraction. Here, we report the discovery of nelutroctiv (CK-136), a selective cardiac troponin activator intended for patients with cardiovascular conditions where cardiac contractility is reduced. Discovery of nelutroctiv began with a high-throughput screen that identified compound 1R, a muscle selective cardiac sarcomere activator devoid of phosphodiesterase-3 activity. Optimization of druglike properties for 1R led to the replacement of the sulfonamide and aniline substituents which resulted in improved pharmacokinetic (PK) profiles and a reduced potential for human drug-drug interactions. In vivo echocardiography assessment of the optimized leads showed concentration dependent increases in fractional shortening and an improved pharmacodynamic window compared to myosin activator CK-138. Overall, nelutroctiv was found to possess the desired selectivity, a favorable pharmacodynamic window relative to myosin activators, and a preclinical PK profile to support clinical development.
Collapse
Affiliation(s)
- Antonio Romero
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Luke Ashcraft
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Aroop Chandra
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Vincent DiMassa
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Peadar Cremin
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Scott E Collibee
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Chihyuan Chuang
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - James Hartman
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Darren T Hwee
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - David St Jean
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Justin Malinowski
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Mikkel DeBenedetto
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - David Moebius
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Joshua Payette
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Richard Vargas
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - John Yeoman
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Alykhan Motani
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Jeffrey Reagan
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Fady I Malik
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Bradley P Morgan
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| |
Collapse
|
2
|
Wang W, Zhang L, Battiprolu PK, Fukushima A, Nguyen K, Milner K, Gupta A, Altamimi T, Byrne N, Mori J, Alrob OA, Wagg C, Fillmore N, Wang SH, Liu DM, Fu A, Lu JY, Chaves M, Motani A, Ussher JR, Reagan JD, Dyck JRB, Lopaschuk GD. Malonyl CoA Decarboxylase Inhibition Improves Cardiac Function Post-Myocardial Infarction. ACTA ACUST UNITED AC 2019; 4:385-400. [PMID: 31312761 PMCID: PMC6609914 DOI: 10.1016/j.jacbts.2019.02.003] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2018] [Revised: 02/04/2019] [Accepted: 02/11/2019] [Indexed: 01/03/2023]
Abstract
MCD inhibition decreases fatty acid oxidation via increasing malonyl coenzyme A levels to prevent fatty acid uptake into mitochondria in the failing hearts induced by coronary artery ligation. Downregulating fatty acid oxidation by MCD inhibition occurrs in conjuction with a decrease in glycolysis and in proton production while an increase in triacylglycerol biosynthesis. MCD inhibition enhances antioxidative capacity through increasing mitochondrial superoxide dismutase activity via reducing its acetylation.
Alterations in cardiac energy metabolism after a myocardial infarction contribute to the severity of heart failure (HF). Although fatty acid oxidation can be impaired in HF, it is unclear if stimulating fatty acid oxidation is a desirable approach to treat HF. Both immediate and chronic malonyl coenzyme A decarboxylase inhibition, which decreases fatty acid oxidation, improved cardiac function through enhancing cardiac efficiency in a post–myocardial infarction rat that underwent permanent left anterior descending coronary artery ligation. The beneficial effects of MCD inhibition were attributed to a decrease in proton production due to an improved coupling between glycolysis and glucose oxidation.
Collapse
Key Words
- ATGL, adipose triglyceride lipase
- CPT1, carnitine palmitoyltransferase 1
- EF, ejection fraction
- FOXO3, forkhead box O3
- MCD, malonyl coenzyme A decarboxylase
- MI, myocardial infarction
- SERCA2, sarco(endo)plasmic reticulum Ca2+-ATPase 2
- SOD, superoxide dismutase
- SPT, serine palmitoyltransferase
- TAG, triacylglycerol
- Trx, thioredoxin
- fatty acid oxidation
- glucose oxidation
- heart failure
- uncoupling of glycolysis
Collapse
Affiliation(s)
- Wei Wang
- Cardiovascular Research Centre, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.,Department of Cardiac Surgery, University of Alberta, Edmonton, Alberta, Canada
| | - Liyan Zhang
- Cardiovascular Research Centre, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
| | | | - Arata Fukushima
- Cardiovascular Research Centre, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
| | | | - Kenneth Milner
- Cardiovascular Research Centre, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
| | - Abhishek Gupta
- Cardiovascular Research Centre, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
| | - Tariq Altamimi
- Cardiovascular Research Centre, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
| | - Nikole Byrne
- Cardiovascular Research Centre, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
| | - Jun Mori
- Cardiovascular Research Centre, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
| | - Osama Abo Alrob
- Cardiovascular Research Centre, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
| | - Cory Wagg
- Cardiovascular Research Centre, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
| | - Natasha Fillmore
- Cardiovascular Research Centre, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
| | - Shao-Hua Wang
- Department of Cardiac Surgery, University of Alberta, Edmonton, Alberta, Canada
| | | | | | | | | | | | - John R Ussher
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
| | | | - Jason R B Dyck
- Cardiovascular Research Centre, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
| | - Gary D Lopaschuk
- Cardiovascular Research Centre, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
| |
Collapse
|
3
|
Yu M, Lizarzaburu M, Motani A, Fu Z, Du X, Liu J(J, Jiao X, Lai S, Fan P, Fu A, Liu Q, Murakoshi M, Nara F, Oda K, Okuyama R, Reagan JD, Watanabe N, Yamazaki M, Xiong Y, Zhang Y, Zhuang R, Lin DCH, Houze JB, Medina JC, Li L. Aminopyrazole-Phenylalanine Based GPR142 Agonists: Discovery of Tool Compound and in Vivo Efficacy Studies. ACS Med Chem Lett 2013; 4:829-34. [PMID: 24900757 DOI: 10.1021/ml4000854] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2013] [Accepted: 05/01/2013] [Indexed: 02/02/2023] Open
Abstract
Herein, we report the lead optimization of amrinone-phenylalanine based GPR142 agonists. Structure-activity relationship studies led to the discovery of aminopyrazole-phenylalanine carboxylic acid 22, which exhibited good agonistic activity, high target selectivity, desirable pharmacokinetic properties, and no cytochrome P450 or hERG liability. Compound 22, together with its orally bioavailable ethyl ester prodrug 23, were found to be suitable for in vivo proof-of-concept studies. Compound 23 displayed good efficacy in a mouse oral glucose tolerance test (OGTT). Compound 22 showed GPR142 dependent stimulation of insulin secretion in isolated mouse islets and demonstrated a statistically significant glucose lowering effect in a mouse model bearing transplanted human islets.
Collapse
Affiliation(s)
- Ming Yu
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080,
United States
| | - Mike Lizarzaburu
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080,
United States
| | - Alykhan Motani
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080,
United States
| | - Zice Fu
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080,
United States
| | - Xiaohui Du
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080,
United States
| | - Jiwen (Jim) Liu
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080,
United States
| | - Xianyun Jiao
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080,
United States
| | - SuJen Lai
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080,
United States
| | - Peter Fan
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080,
United States
| | - Angela Fu
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080,
United States
| | - Qingxiang Liu
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080,
United States
| | - Michiko Murakoshi
- Daiichi-Sankyo, 1-2-58 Hiromachi, Shinagawa-Ku, Tokyo
140-8710; 1-16-13 Kitakasai,
Edogawa-Ku, Tokyo 134-8650, Japan
| | - Futoshi Nara
- Daiichi-Sankyo, 1-2-58 Hiromachi, Shinagawa-Ku, Tokyo
140-8710; 1-16-13 Kitakasai,
Edogawa-Ku, Tokyo 134-8650, Japan
| | - Kozo Oda
- Daiichi-Sankyo, 1-2-58 Hiromachi, Shinagawa-Ku, Tokyo
140-8710; 1-16-13 Kitakasai,
Edogawa-Ku, Tokyo 134-8650, Japan
| | - Ryo Okuyama
- Daiichi-Sankyo, 1-2-58 Hiromachi, Shinagawa-Ku, Tokyo
140-8710; 1-16-13 Kitakasai,
Edogawa-Ku, Tokyo 134-8650, Japan
| | - Jeff D. Reagan
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080,
United States
| | - Nobuaki Watanabe
- Daiichi-Sankyo, 1-2-58 Hiromachi, Shinagawa-Ku, Tokyo
140-8710; 1-16-13 Kitakasai,
Edogawa-Ku, Tokyo 134-8650, Japan
| | - Mami Yamazaki
- Daiichi-Sankyo, 1-2-58 Hiromachi, Shinagawa-Ku, Tokyo
140-8710; 1-16-13 Kitakasai,
Edogawa-Ku, Tokyo 134-8650, Japan
| | - Yumei Xiong
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080,
United States
| | - Ying Zhang
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080,
United States
| | - Run Zhuang
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080,
United States
| | - Daniel C.-H. Lin
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080,
United States
| | - Jonathan B. Houze
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080,
United States
| | - Julio C. Medina
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080,
United States
| | - Leping Li
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080,
United States
| |
Collapse
|
4
|
Toda N, Hao X, Ogawa Y, Oda K, Yu M, Fu Z, Chen Y, Kim Y, Lizarzaburu M, Lively S, Lawlis S, Murakoshi M, Nara F, Watanabe N, Reagan JD, Tian H, Fu A, Motani A, Liu Q, Lin YJ, Zhuang R, Xiong Y, Fan P, Medina J, Li L, Izumi M, Okuyama R, Shibuya S. Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes. ACS Med Chem Lett 2013; 4:790-4. [PMID: 24900747 DOI: 10.1021/ml400186z] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2013] [Accepted: 06/16/2013] [Indexed: 01/07/2023] Open
Abstract
GPR142 is a G protein-coupled receptor that is predominantly expressed in pancreatic β-cells. GPR142 agonists stimulate insulin secretion in the presence of high glucose concentration, so that they could be novel insulin secretagogues with reduced or no risk of hypoglycemia. We report here the optimization of HTS hit compound 1 toward a proof of concept compound 33, which showed potent glucose lowering effects during an oral glucose tolerance test in mice and monkeys.
Collapse
Affiliation(s)
- Narihiro Toda
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710,
Japan
| | - Xiaolin Hao
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco,
California 94080,
United States
| | - Yasuyuki Ogawa
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710,
Japan
| | - Kozo Oda
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710,
Japan
| | - Ming Yu
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco,
California 94080,
United States
| | - Zice Fu
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco,
California 94080,
United States
| | - Yi Chen
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco,
California 94080,
United States
| | - Yongjae Kim
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco,
California 94080,
United States
| | - Mike Lizarzaburu
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco,
California 94080,
United States
| | - Sarah Lively
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco,
California 94080,
United States
| | - Shauna Lawlis
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco,
California 94080,
United States
| | - Michiko Murakoshi
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710,
Japan
| | - Futoshi Nara
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710,
Japan
| | - Nobuaki Watanabe
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710,
Japan
| | - Jeff D. Reagan
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco,
California 94080,
United States
| | - Hui Tian
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco,
California 94080,
United States
| | - Angela Fu
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco,
California 94080,
United States
| | - Alykhan Motani
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco,
California 94080,
United States
| | - Qingxiang Liu
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco,
California 94080,
United States
| | - Yi-Jyun Lin
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco,
California 94080,
United States
| | - Run Zhuang
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco,
California 94080,
United States
| | - Yumei Xiong
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco,
California 94080,
United States
| | - Peter Fan
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco,
California 94080,
United States
| | - Julio Medina
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco,
California 94080,
United States
| | - Leping Li
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco,
California 94080,
United States
| | - Masanori Izumi
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710,
Japan
| | - Ryo Okuyama
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710,
Japan
| | - Satoshi Shibuya
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710,
Japan
| |
Collapse
|
5
|
Taygerly JP, McGee LR, Rubenstein SM, Houze JB, Cushing TD, Li Y, Motani A, Chen JL, Frankmoelle W, Ye G, Learned MR, Jaen J, Miao S, Timmermans PB, Thoolen M, Kearney P, Flygare J, Beckmann H, Weiszmann J, Lindstrom M, Walker N, Liu J, Biermann D, Wang Z, Hagiwara A, Iida T, Aramaki H, Kitao Y, Shinkai H, Furukawa N, Nishiu J, Nakamura M. Discovery of INT131: A selective PPARγ modulator that enhances insulin sensitivity. Bioorg Med Chem 2013; 21:979-92. [DOI: 10.1016/j.bmc.2012.11.058] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2012] [Revised: 11/20/2012] [Accepted: 11/24/2012] [Indexed: 01/08/2023]
|
6
|
Du X, Kim YJ, Lai S, Chen X, Lizarzaburu M, Turcotte S, Fu Z, Liu Q, Zhang Y, Motani A, Oda K, Okuyama R, Nara F, Murakoshi M, Fu A, Reagan JD, Fan P, Xiong Y, Shen W, Li L, Houze J, Medina JC. Corrigendum to “Phenylalanine derivatives as GPR142 agonists for the treatment of Type II diabetes” [Bioorg. Med. Chem. Lett. 22 (2012) 6218–6223]. Bioorg Med Chem Lett 2012. [DOI: 10.1016/j.bmcl.2012.10.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
7
|
Yu M, Lizarzaburu M, Beckmann H, Connors R, Dai K, Haller K, Li C, Liang L, Lindstrom M, Ma J, Motani A, Wanska M, Zhang A, Li L, Medina JC. Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity. Bioorg Med Chem Lett 2010; 20:1758-62. [DOI: 10.1016/j.bmcl.2010.01.043] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2009] [Revised: 01/05/2010] [Accepted: 01/06/2010] [Indexed: 01/21/2023]
|
8
|
Motani A, Wang Z, Conn M, Siegler K, Zhang Y, Liu Q, Johnstone S, Xu H, Thibault S, Wang Y, Fan P, Connors R, Le H, Xu G, Walker N, Shan B, Coward P. Identification and characterization of a non-retinoid ligand for retinol-binding protein 4 which lowers serum retinol-binding protein 4 levels in vivo. J Biol Chem 2009; 284:7673-80. [PMID: 19147488 PMCID: PMC2658061 DOI: 10.1074/jbc.m809654200] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2008] [Indexed: 11/06/2022] Open
Abstract
Retinol-binding protein 4 (RBP4) transports retinol from the liver to extrahepatic tissues, and RBP4 lowering is reported to improve insulin sensitivity in mice. We have identified A1120, a high affinity (K(i) = 8.3 nm) non-retinoid ligand for RBP4, which disrupts the interaction between RBP4 and its binding partner transthyretin. Analysis of the RBP4-A1120 co-crystal structure reveals that A1120 induces critical conformational changes at the RBP4-transthyretin interface. Administration of A1120 to mice lowers serum RBP4 and retinol levels but, unexpectedly, does not improve insulin sensitivity. In addition, we show that Rpb4(-/-) mice display normal insulin sensitivity and are not protected from high fat diet-induced insulin resistance. We conclude that lowering RBP4 levels does not improve insulin sensitivity in mice. Therefore, RBP4 lowering may not be an effective strategy for treating diabetes.
Collapse
Affiliation(s)
- Alykhan Motani
- Department of Metabolic Disorders, Amgen, Inc., South San Francisco, California 94080, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
IGF-I is a ubiquitous growth factor, found in platelets and elaborated by many other cell types. It is thought to be involved in several pathophysiological processes including embryonic development, angiogenesis and wound healing. We report that the adherence of human peripheral blood monocytes to an endothelial cell line (EAhy 926) is inhibited in a dose and time-dependent manner by pre-incubating the endothelial cells with IGF-I (P < 0.001). Monocyte adhesion was inhibited 17.9 +/- 1.9% by IGF-I at a dose of 1000 ng/ml (P < 0.01). In contrast, IGF-I had no significant effect on monocyte adherence to plastic. The inhibitory effects of IGF-I were reversed by co-incubating the endothelial cells with the nitric oxide synthase inhibitor, L-NAME. These data suggest that the effects of IGF-I are mediated by the release of nitric oxide from the endothelial cells.
Collapse
Affiliation(s)
- A Motani
- William Harvey Research Institute, London, UK
| | | | | | | | | |
Collapse
|
10
|
Motani A, Rutherford C, Anggard EE, Ferns GA. Insulin-like growth factor binding protein-1 inhibits arterial smooth muscle cell proliferation in vitro but does not reduce the neointimal response to balloon catheter injury. Atherosclerosis 1995; 118:57-66. [PMID: 8579632 DOI: 10.1016/0021-9150(95)05593-l] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The biological effects of the insulin-like growth factors (IGFs) are modulated by circulating binding proteins (BPs), including IGFBP-1. We have investigated the effects of recombinant IGFBP-1 on smooth muscle cell (SMC) proliferation in vitro using cultured rat aortic SMCs and in vivo using the ballooned rat carotid artery model. IGFBP-1 inhibited IGF-1 induced and spontaneous SMC proliferation dose-dependently. In vivo, the effective half-life of IGFBP-1 was approximately 5 h when administered by intraperitoneal injection. High peri-operative plasma levels of IGFBP-1 (mean 1780 ng/ml) were attained by giving and intravenous dose immediately prior to balloon injury in 9 rats. Animals injected with human serum albumin or saline were used as controls. In vivo cell proliferation was assessed by BrdU pulse labeling each animal prior to the termination of the experiment, 6 days after balloon injury. Absolute intimal thickness, intima-media ratio and cell proliferation indices were measured for each animal. Although IGFBP-1 inhibited SMC proliferation in vitro, high plasma concentrations of IGFBP-1 did not reduce neointimal size or cell proliferation. IGFBP-1 administration was, however, associated with a significantly greater loss of body weight (P < 0.05), indicating that the peptide had a profound metabolic effect. Our data suggest that IGF-1 does not have a major role in inducing SMC proliferation in the early phases following angioplasty.
Collapse
MESH Headings
- Animals
- Aorta, Thoracic/cytology
- Aorta, Thoracic/drug effects
- Carotid Artery Injuries
- Carotid Artery, Common/drug effects
- Carotid Artery, Common/pathology
- Catheterization
- Cell Division/drug effects
- Cells, Cultured
- DNA/biosynthesis
- Dose-Response Relationship, Drug
- In Vitro Techniques
- Insulin-Like Growth Factor Binding Protein 1/pharmacology
- Male
- Muscle, Smooth, Vascular/cytology
- Muscle, Smooth, Vascular/drug effects
- Muscle, Smooth, Vascular/metabolism
- Rats
- Rats, Wistar
- Tunica Intima/pathology
Collapse
Affiliation(s)
- A Motani
- William Harvey Research Institute, London, UK
| | | | | | | |
Collapse
|